Document is current

Article History

Received: 23 January 2019

Accepted: 30 May 2019

First Online: 14 June 2019

Compliance with ethical standards

: All volunteers provided written informed consent. The study was approved by the Cambridge Research Ethics Committee.

: Dr. Bullmore is employed half-time by GSK and half-time by University of Cambridge. He holds stock in GSK. Dr. Craig was employed by the University of Cambridge at the time the study was initiated; he is now employed by, and holds stock in, Covance, the drug development business of Laboratory Corporation of America® Holdings (LabCorp). Dr. Fineberg reports the following commercial interests, all outside the research work; in the past 2 years, she has received personal fees for giving lectures from Abbott, Otsuka-Lundbeck, RANZCP, BAP, and Wiley; payment for editorial duties from Taylor and Francis; royalties from Oxford University Press; payment for consultancy from the MHRA; research or educational grants from Shire, ECNP, NIHR, MRC, and Wellcome Trust; and non-financial support from Shire, ECNP, BAP, CINP, International Forum of Mood and Anxiety Disorders, International College of Obsessive Compulsive Spectrum Disorders, and RCPsych. Dr. Robbins discloses consultancy with Cambridge Cognition, Lundbeck, Mundipharma, and Unilever; he receives royalties for CANTAB from Cambridge Cognition and editorial honoraria from Springer Verlag and Elsevier. Dr. Sahakian consults for Cambridge Cognition, Peak (Brainbow), and Mundipharma. Ms. Shabbir is employed by GSK. Drs. Abbott, Ersche, Knolle, Murray, and Suckling declare no competing interests.